Researchers at Vanderbilt University Medical Center have found that people recovering from COVID-19 and those vaccinated against the causative virus, SARS-CoV-2, produce identical clones, or groups, of antibody-producing white blood cells.

Vanderbilt University Medical Center completed its first full fiscal year of the COVID-19 era having achieved remarkable outcomes in digital health, growth and quality because of consistently strong performance from its workforce.

Physicians at Vanderbilt University Medical Center (VUMC) have recently noticed an increase in pregnant patients ill with COVID-19. These cases are especially concerning due an increased risk of hospitalization, ICU admission, need for mechanical ventilation and ventilatory support, and increased risk of death in pregnant patients with COVID-19 compared to non-pregnant patients.

Vanderbilt University Medical Center and the Vanderbilt Transplant Center have won Platinum Recognition, the highest possible level of achievement, from the National Hospital Organ Donation Campaign of the U.S. Department of Health and Human Services, Health Resources and Services Administration (HRSA).

A report of more than 23,000 health care workers and employees at Vanderbilt University Medical Center who received the Pfizer-BioNTech mRNA COVID-19 vaccine shows that a risk stratification screening mechanism for potential allergies to the vaccine worked exceedingly well as the vaccine program rolled out in December 2020.

An immediate allergic reaction to the first dose of an mRNA COVID-19 vaccine — those manufactured by Moderna and Pfizer BioNTech — should not keep people from getting the second dose, a multi-hospital analysis shows.

Vanderbilt University Medical Center researchers, supported by the National Institutes of Health (NIH), are leading a nationwide clinical trial to explore the safety and effectiveness of a group of novel drugs designed to protect patients hospitalized with COVID-19 at high risk of poor outcomes.